Equities

Embecta Corp

Embecta Corp

Actions
  • Price (MXN)497.96
  • Today's Change0.00 / 0.00%
  • Shares traded3.00
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of May 16 2023 12:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Embecta Corp. is a global diabetes care company. It is focused on providing solutions to people living with diabetes. It has a portfolio of products, including a range of pen needles, syringes and safety injection devices, which are complemented by its digital application designed to assist people with managing their diabetes. Its pen needles are sterile, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. It sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. In addition to pen needles, it sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. It has clearance from the FDA for its proprietary disposable insulin delivery system, which is indicated for adults who require insulin to manage diabetes, including both type 1 (T1D) and type 2 (T2D).

  • Revenue in USD (TTM)1.12bn
  • Net income in USD69.70m
  • Incorporated2021
  • Employees2.20k
  • Location
    Embecta Corp300 Kimball Drive, Suite 300PARSIPPANY NJ 07054United StatesUSA
  • Phone+1 (862) 401-0000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.embecta.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.